Clinical Research

Activating mutations in PIK3CA (the gene encoding the p110α catalytic subunit of class I phosphatidylinositol 3-kinase [PI3K] [PI3Kα]) lead to increased activity of the PI3K pathway and play a role in endocrine treatment resistance in breast cancer.
Evidence exists showing that enabling patients to engage in treatment decisions through education and shared decision-making is an effective tool in promoting self-efficacy, reducing barriers to care, and increasing the perceived benefits of self-involvement in one’s cancer diagnosis and treatment plan.
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for the delivery of androgen deprivation therapy (ADT) in prostate cancer (PCa).
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.
Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/K–mutant stage III melanoma.
Page 3 of 6
Results 21 - 30 of 60

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country